A Phase 1 First In Human, Multicenter, Open label Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In Subjects With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

05 Oct 2022 According to a ChemoCentryx media release, results from this trial will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting 2022 (Abstract Number: 769).
07 Jun 2022 Interim results (n=9; data cut off date- 1 feb 2022) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
06 Jun 2022 Results (n=13) published in the ChemoCentryx Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com